Inspiremd Inc (NSPR)

$2.26 +0.01 (0.44%)
Market Cap 94.29M
Revenue (ttm) 7.01M
Net Income (ttm) -32.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.63%
Debt to Equity Ratio 0.00
Volume 10,500
Avg Vol 92,524
Day's Range N/A - N/A
Shares Out 41.72M
Stochastic %K 18%
Beta 0.60
Analysts Strong Sell
Price Target $4.50

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
Ronnie5isAlive
Ronnie5isAlive Oct. 26 at 1:23 AM
$NSPR you have to wonder if this will be one of those “why didn’t buy this at $2?!” moments in a month or two when the chart shows it at $20+?
0 · Reply
ALWAYSGOOD
ALWAYSGOOD Oct. 24 at 11:09 PM
$NSPR Quarterly results on 4th November?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.27 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.17- $1.44 Scale out: $1.83-$2.35 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LoyalShark
LoyalShark Oct. 24 at 2:47 PM
$NSPR Biggest PIECE OF SHIT CEO on EARTH --- Slosman. What a FKN NIGHTMARE this guy is.
1 · Reply
JBinLB
JBinLB Oct. 24 at 1:42 PM
$NSPR you guys buying up these cheapies right??! 😂
2 · Reply
arcuy
arcuy Oct. 23 at 5:18 PM
$NSPR shake shake shake, shake shake shake, shake your booty
0 · Reply
JBinLB
JBinLB Oct. 23 at 1:15 AM
$NSPR $2.20s!!! Let’s do another RS 🙏🏼
0 · Reply
Threeways
Threeways Oct. 21 at 8:17 PM
$NSPR Earnings 11/4 LETS GOOOO
1 · Reply
Threeways
Threeways Oct. 21 at 6:36 PM
$NSPR fun fact: Inspiremd announced FDA approval 6/24 and then announced US commercial launch 7/9. First official US patient procedure then happened on 7/11 in Round Rock Tx, to 84 year old Paul Hargadon of Georgetown Tx. While NSPRs PR is very very weak on reporting or giving any sort of guidance or updates. I have a feeling earnings might look more attractive than we are being led to believe from their silence.
2 · Reply
JBinLB
JBinLB Oct. 21 at 1:13 PM
$NSPR it was months of $2.50s then months of $2.40s and now we’ve entered the $2.30s era
0 · Reply
Latest News on NSPR
InspireMD to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:05 PM EDT - 4 days ago

InspireMD to Announce Third Quarter 2025 Financial Results

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 8, 2025, 8:00 AM EDT - 17 days ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Sep 17, 2025, 8:00 AM EDT - 5 weeks ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 9:00 AM EDT - 2 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 12:30 PM EDT - 2 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

InspireMD Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 2 months ago

InspireMD Reports Second Quarter 2025 Financial Results

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:31 AM EDT - 3 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

InspireMD Announces Combined Financings of $58 Million

Jul 31, 2025, 8:30 AM EDT - 3 months ago

InspireMD Announces Combined Financings of $58 Million

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 3 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jul 9, 2025, 7:00 AM EDT - 3 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 4 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 4 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

Jun 3, 2025, 4:05 PM EDT - 5 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:07 PM EDT - 6 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 6 months ago

InspireMD Reports First Quarter 2025 Financial Results

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 30, 2025, 9:00 AM EDT - 6 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 6 months ago

InspireMD to Announce First Quarter 2025 Financial Results

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 9:00 AM EDT - 7 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 1:53 PM EDT - 8 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 12, 2025, 7:00 AM EDT - 8 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 8 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Feb 13, 2025, 7:00 AM EST - 9 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Dec 9, 2024, 7:00 AM EST - 11 months ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 25, 2024, 4:05 PM EST - 11 months ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Jan 3, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Dec 20, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 27, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:09 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

InspireMD to Participate in Upcoming November Investor Conferences

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InspireMD to Participate in Upcoming November Investor Conferences

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Nov 1, 2023, 2:19 PM EDT - 2 years ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Ronnie5isAlive
Ronnie5isAlive Oct. 26 at 1:23 AM
$NSPR you have to wonder if this will be one of those “why didn’t buy this at $2?!” moments in a month or two when the chart shows it at $20+?
0 · Reply
ALWAYSGOOD
ALWAYSGOOD Oct. 24 at 11:09 PM
$NSPR Quarterly results on 4th November?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 4:21 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.27 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.17- $1.44 Scale out: $1.83-$2.35 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LoyalShark
LoyalShark Oct. 24 at 2:47 PM
$NSPR Biggest PIECE OF SHIT CEO on EARTH --- Slosman. What a FKN NIGHTMARE this guy is.
1 · Reply
JBinLB
JBinLB Oct. 24 at 1:42 PM
$NSPR you guys buying up these cheapies right??! 😂
2 · Reply
arcuy
arcuy Oct. 23 at 5:18 PM
$NSPR shake shake shake, shake shake shake, shake your booty
0 · Reply
JBinLB
JBinLB Oct. 23 at 1:15 AM
$NSPR $2.20s!!! Let’s do another RS 🙏🏼
0 · Reply
Threeways
Threeways Oct. 21 at 8:17 PM
$NSPR Earnings 11/4 LETS GOOOO
1 · Reply
Threeways
Threeways Oct. 21 at 6:36 PM
$NSPR fun fact: Inspiremd announced FDA approval 6/24 and then announced US commercial launch 7/9. First official US patient procedure then happened on 7/11 in Round Rock Tx, to 84 year old Paul Hargadon of Georgetown Tx. While NSPRs PR is very very weak on reporting or giving any sort of guidance or updates. I have a feeling earnings might look more attractive than we are being led to believe from their silence.
2 · Reply
JBinLB
JBinLB Oct. 21 at 1:13 PM
$NSPR it was months of $2.50s then months of $2.40s and now we’ve entered the $2.30s era
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 2:41 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.32 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.20- $1.46 Scale out: $1.86-$2.39 Can Easily Capture: 60% ROI Blended DTE: 208 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LoyalShark
LoyalShark Oct. 18 at 10:29 AM
$NSPR Slosman is the problem. He has shit on the retail investor for 6years. He lacks understanding. He lacks wisdom. He lacks what every great public CEO has -- Market IQ. We are destroyed by one guys ignorance of how to create value for SHAREHOLDERS...like in STOCK PRICE ...in the markets. If Nov revs are as shitty as I expect -- I will sell and move on. Fk Slosman.
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 5:27 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.38 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $0.41- $0.51 Scale out: $0.64-$0.83 Can Easily Capture: 60% ROI Blended DTE: 210 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Oct. 17 at 5:39 PM
$NSPR Good God my portfolio is pure bloodbath. Dumped $BITF $PZG early so I still got out with some minimal gains. I WILL get back in those when the entry looks more favorable - the future of $BITF & $PZG is too bright to ignore. Ironically $NSPR is the last and ONLY position I'm bag holding. I HATE bag holding. However $NSPR has held their gains best over the long term especially when the market dumps. Hmmmmm... Still holding and adding to $SOFI and $AUST.
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 16 at 11:07 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.38 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.20- $1.46 Scale out: $1.86-$2.39 Can Easily Capture: 60% ROI Blended DTE: 211 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
abdolfos
abdolfos Oct. 16 at 2:08 PM
$NSPR the question is when and how much...not if...
1 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 15 at 10:35 PM
$NSPR you have to love watching these high flyers with no sales or revenue trading on future earnings at insane market caps. Then there is us. Sitting here like the bastard children of the market. Will we have our day soon? Will it be fast? Or painfully slow crawl up like more Chinese water torture?
2 · Reply
arcuy
arcuy Oct. 15 at 10:07 PM
$NSPR less than a month
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 15 at 8:26 PM
$NSPR like being trapped in a basement well. “It puts the lotion on its skin!!”
0 · Reply
Meterdoc
Meterdoc Oct. 15 at 1:18 PM
$NSPR years and years of comedy on this thread.
3 · Reply
LoyalShark
LoyalShark Oct. 15 at 11:07 AM
$NSPR Anyone have an idea why this trades like a POS?
2 · Reply
JBinLB
JBinLB Oct. 14 at 2:06 PM
$NSPR goes down in a down market, stays flat in an upmarket. 💩
0 · Reply